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1. Introduction 
The adrenal cortex tumors include both malignant adrenal cortex cancers (ACC) and benign 
masses (ACT) that can be either secreting, of one of the hormones normally produced in the 
adrenal cortex (Cushing’s syndrome if the hypersecretion is of cortisol or Conn’s syndrome 
if it is aldosterone) or non-secretory (Incidentalomas).  
The outer part of the adrenal glands, the adrenal cortex, is responsible for regulating important 
body functions including blood sugar levels, body water and salt levels, and consequently 
blood pressure and kidney functions, the immune system, the inflammatory response, the 
physiological response to stress, and, finally, sexual and reproductive functions.  
The three different parts of the adrenal cortex, zona glomerulosa, zona fasciculata and zona 
reticularis, are responsible for producing different hormones namely mineralocorticoids, 
glucocorticoids, and androgens (and eventually also estrogens). The glomerulosa secretes 
aldosterone, and gives rise to Primary Aldosteronism (PA)/Hyperaldosteronism that can 
result either from an adenoma (Conn’s syndrome) or from bilateral hyperplasia (BAH). The 
zona fasciculata secretes cortisol and adenomas that produce this hormone are associated to a 
distinct syndrome called Cushing’s syndrome. Finally the adrenal cortex reticularis zone is 
supposed to produce adrenal androgens (namely dehydroepiandrosterone – DHEA and 
dehydroepiandrosterone sulfate – DHEA-s) that can in turn be either converted into 
testosterone or aromatized to estrogen in peripheral organs like the adipose tissue. In spite 
of the fact that normally this peripheral conversion is more important than the local 
production, there are adrenal cortex tumors that can produce testosterone directly, the 
Androgen-secreting tumors as well as adrenocortical carcinomas expressing aromatase and 
producing estrogens, the Estrogen-secreting tumors.  
The majority of adrenocortical tumors (ACT) are benign and silent (non-secreting adenomas 
or incidentalomas) since they do not ever result in hormone secretion. Its true incidence is 
still unknown because it is probable that many of these cases still go undiagnosed. 
However, it is estimated that they are present in at least 3% of the adult population 
(especially over 50 years of age) (National Institutes of Health, 2002; Grumbach et al., 2003). 
Most of these tumors are discovered incidentally due to the widespread availability of 
imaging studies for intra-abdominal diseases. This is the reason why they are designated as 
Incidentalomas.  
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In summary, only a minority of the adrenocortical benign tumors (about 15%) are hormone-
secreting adenomas, responsible for Cushing’s syndrome, primary aldosteronism (Conn’s 
syndrome) or even sometimes virilization. 
Adrenocortical carcinoma is a rare, highly malignant tumor usually associated with a poor 
prognosis which may occur either in children or adults. This is a malignancy with an 
heterogeneous presentation and despite probably still underestimated it has an expected 
incidence of about 1-2 cases per 1 million population per year (Wajchenberg et al., 2000; 
Dackiw et al., 2001; Kebebew et al., 2006). Although the adrenocortical carcinomas may 
occur and develop at any age, two different disease peaks were identified, one before the 
age of five and the other in the fifth decade of life (Wajchenberg et al., 2000; Ng & Libertino, 
2003).  
2. Adrenal cortex cancer 
The evaluation and categorization of adrenocortical neoplasms remain among the most 
challenging areas in adrenal pathology (Lau & Weiss, 2009), since the pathological diagnosis 
of ACC, which is based on gross and microscopic criteria, is still full of areas of subjectivity. 
Moreover, in the absence of the gold standards that constitute the appearance of metastases, 
local invasion or recurrence, the diagnosis of malignancy may represent a great difficulty for 
both clinicians and pathologists.  
Several multiparametric systems have been developed to assess this malignancy (Aubert, 
2005). Among them, the Weiss system (Weiss, 1984), first introduced 25 years ago, and 
based on nine microscopic criteria, appears to be the most employed scoring methodology, 
because of its simplicity and reliability.  
This system provides specific guidelines for differentiating adrenocortical adenoma from 
adrenocortical carcinoma and is considered the standard for determining malignancy in 
tumors of the adrenal cortex. However, considerable advances in the understanding of the 
pathology of adrenocortical neoplasias have occurred since delineation of the Weiss system, 
offering alternative approaches in the contemporary assessment of adrenocortical tumors 
(Lau & Weiss, 2009). In a recent study based on whole genome gene analysis the authors 
proposed a molecular assay for the classification and prognosis of adrenocortical tumors 
(Giordano et al., 2009). There were many genetic expression differences between ACC and 
ACT and normal adrenals. There were in fact 879 genes over expressed and 1011 under 
expressed in ACC that could differentiate ACC from ACT and normal adrenals. The most 
significant ones were related to cell proliferation, as would be expected. But the reality is 
that such systems are still very expensive and add very little to the diagnostic power of the 
morphological analyses. Therefore, in most adrenocortical tumors, the morphological 
approach considering the probability of malignancy in adrenal masses > 6 cm and that of 
being benign in tumors < 4 cm, together with the postoperative assessment by the Weiss 
system, brings sufficient elements to establish the differential diagnosis between a benign 
and a malignant tumor (Tissier, 2010). 
The Weiss system, which, as previously was said,  is currently the most popular scoring 
system, combines nine morphological parameters, of which three are structural ("dark" 
cytoplasm, diffuse architecture, necrosis), three are cytological (atypia, mitotic count, 
atypical mitotic figures) and three are related to invasion (of sinusoids, veins and tumor 
capsule) (Volante et al., 2008). The nine histological criteria are:  
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 High nuclear grade (grades 3 or 4) (High Nuclear/Cytoplasm ratio; marked 
variation of nuclear characteristics; giant cells with hyperchromatic nuclei; visible 
nucleoli) 
1. Small roundish nuclei; without nucleoli  
2. Larger nuclei, more irregular in shape and with visible nucleoli (at 400x 
magnification) 
3. Irregular nuclei, with larger size, with visible nucleoli (at 100x) 
4. enormous cells with polylobulated nuclei 
 Mitoses (>5 per 50 HPF vs. <6)  
 Abnormal mitoses (absent vs. present) 
 Clear cells (≤25% vs. >25%) 
 Diffuse architecture (>33% vs. ≤33% of the area) (cells unorganized in trabecular or 
alveolar structures) 
 Necrosis (present vs. absent) 
 Venous invasion (present vs. absent) 
 Sinusoidal invasion (present vs. absent) 
 Capsular invasion (present vs. absent) 
1. Nuclear grade: nuclear grade III and IV based on criteria of Fuhrman (Fuhrman et al., 1982). 
2. Mitotic rate: greater than 5/50 HPF (x400 objective). According to Weiss, "mitosis was evaluated 
by counting 10 random high-power-fields in the area of the greatest numbers of mitotic figures 
on the five slides with greatest number of mitoses. If less than five slides were available for a 
case, a correspondingly greater number of fields per slide were used to make fifty high power-
fields." 
3. Atypical mitotic figures: "mitosis was regarded as atypical when it definitely showed an abnormal 
distribution of chromosomes or an excessive number of mitotic spindles." 
4. Cytoplasm: presence of ≤25% "clear or vacuolated cells resembling the normal zona fasciculata." 
5.  Diffuse architecture: diffuse architecture was present "if greater than one-third of the tumor 
formed patternless sheets of cells." Trabecular, columnar, alveolar or nesting organizations were 
regarded as non-diffuse patterns. 
6. Necrosis: necrosis was "regarded as present when occurring in at least confluent nests of cells." 
7. Venous invasion: Weiss defined a vein as an "endothelial-lined vessel with smooth muscle as a 
component of the wall." 
8. Sinusoid invasion: a sinusoid was defined as "endothelial-lined vessel in the adrenal gland with 
little supportive tissues." Only sinusoids located within the tumor were considered. 
9. Invasion of tumor capsule: "invasion of the capsule was accepted as present when nests or cords of 
tumor extended into or through the capsule, with a corresponding stroma reaction." 
 
 
 
 
 
Fig. 1. Weiss classification 
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Tumors are classified as malignant when they meet 4 or more of these histological 
criteria. However, it must be stated that there are still some difficulties and subjectivity 
in the application of this system. Also, whether the presence of 3 criteria represents 
malignancy, is still controversial (Aubert et al., 2005). But, despite the referred limitations 
and subjectivity the Weiss classification is still the most reliable and most used criteria 
system. 
Other markers not included in the Weiss scores are now perfectly identified as being 
associated with the risk of recurrence and lower survival. Ki67 expression ≥ 10% for 
instance is associated with much less chances of survival at 5 years. The same can be said 
about a high expression of    SF-1. The immuno-histochemistry of these two factors is now 
routine in most pathology labs.  (Fassnacht et al., 2011; Sbiera et al., 2010; Terzolo et al., 
2001) 
2.1 Adrenal cortex cancer pathogenesis 
Molecular studies support the fact that uncontrolled cell proliferation is probably the 
most important factor in the development of cancers and ACC is no exception. ACC 
consist of monoclonal populations of cells (Beuschlein et al., 1994) while for instance 
adrenocortical macronodular hyperplasias are usually polyclonal. It is a basic rule that 
the mutations that give rise to cancer development are deletions of tumor suppressor 
genes or amplifications of oncogenes. The increase in cell proliferation induced by 
growth factors like the IGFs, bFGF or TGF ǃ1 (Feige et al., 1991; Mesiano et al., 1991; 
Mesiano et al., 1993) leads to the development of polyclonal tumors but also renders the 
cells more susceptible to mutations in tumor suppressor genes or in oncogenes and if 
these mutations give those cells a genetic advantage, cancer development may ensue.  
Genomic instability is the basis of gross chromosomal alterations and aneuploidy 
(Giordano et al., 2009).  
Most cases of adrenocortical cancers appear to be sporadic and only a small percentage of 
patients present ACC as a component of one of the known hereditary cancer syndromes, 
such as the Li-Fraumeni’s syndrome, the Beckwith-Wiedemann syndrome or the Multiple 
Endocrine Neoplasia type 1 (Koch et al., 2002; Sidhu et al., 2004; Libé & Bertherat, 2005; 
Kjellman et al., 1999; Schulte et al., 2000; Heppner et al., 1999).  
One important difference between these two forms of adrenocortical carcinomas (either 
sporadic or part of an hereditary syndrome) is the current degree of knowledge about its 
tumorigenesis (Soon et al., 2008).  For sporadic adrenocortical malignant tumors the 
molecular mechanisms underlying its development are still far from completely understood 
(Sidhu et al, 2002). One hypothesis refers the possible evolution of adrenocortical cancers 
from adrenal adenomas (Bernard et al., 2003); however long-term follow-up data of 
incidentally discovered adrenal neoplasms do not support that hypothesis (Barzon et al., 
2003; Bernini et al., 2005).  
The study and investigation of the pathophysiology of ACC is not only crucial for the 
understanding of these malignant tumors but also for the development of more sensitive 
means of diagnosis and better ways of treatment. And despite the fact that knowledge of 
these tumors has greatly evolved in the last decades, the understanding of the genes and 
pathways underlying the development of adrenal cortex cancers has been slow. Many genes 
and pathways are thought to play an important role in their development but frequently 
their biological plausibility is still missing.  
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Hereditary tumor 
syndrome 
Gene (locus) Prevalence of ACT 
Li-Fraumeni syndrome 
(LFS) 
TP53 (17p13), HIC-1 (17p13), 
hCHK2 (22q12.1) 
ACC 3%-4% 
Beckwith-Wiedemann 
syndrome  
(BWS) 
IGF-II, H19, CDKN1C (p57kip2), 
KCNQ1 (11p15) 
ACC 5% 
Multiple Endocrine 
Neoplasia 1  
(MEN-1) 
Menin gene (11q13) 
ACT 25-50%; 
ACC rare 
Congenital Adrenal 
Hyperplasia  
(CAH) 
Mostly CYP21B (6p21.3) 
ACT in up to 82%; 
ACC (rare) vs Hyperplasia 
(usual) 
 In LFS there is a germline mutation of the tumor suppressor gene TP53 in more than 70% of the 
families. Tumors associated with this syndrome include breast carcinoma; soft tissue sarcoma; 
brain tumors; osteosarcoma; leukemia and ACC. Mutations in Checkpoint Kinase 2 gene (hCHK2) 
encoding a kinase that phosphorylates TP53 were identified in some of these tumors but not in 
ACC (Libé & Bertherat, 2005).  
 In BWS there is, on the contrary, deregulation of the imprinted IGF-II locus at 11p15. The IGF-II 
gene is maternally imprinted and so it’s expressed only from the paternal allele. H19 and 
p57kip2 are paternally imprinted. In cases of paternal isodisomy, IGF-II is over-expressed and 
H19 and p57kip2 are under-expressed! BWS is a syndrome of “overgrowth” that includes many 
tumors like the renal’ Wilms tumor, ACC, neuroblastoma and hepatoblastoma (Libé & 
Bertherat, 2005).   
 In MEN-1 the germline mutation is in the Menin gene (90% of the families). This gene is also a 
tumor suppressor gene and it is located in chromosome 11 (11q13). LOH at 11q13 exist in more 
than 90% of ACC (Kjellman et al., 1999; Schulte et al., 2000; Heppner et al., 1999) 
Adapted from Soon P. et al., (2008). Molecular markers and the pathogenesis of adrenocortical cancer. 
The Oncologist 13: 548-561 
Table 1. Hereditary tumor syndromes, responsible genes and associated ACT prevalence 
In sporadic ACC it has been reported that hyper-expression of the insulin-like growth factor 
II (IGF-II) is observed in the vast majority of cases (Boulle et al., 1998; Gicquel et al., 1994; 
Gicquel et al., 1997; Gicquel et al., 2001; Ilvesmaki et al., 1993).  Together with the increase of 
this growth factor there is also an increased expression of its receptor (IGF-IR) in most ACC 
(Weber et al., 1997). The over-expression of IGF-II is probably related to adrenal cancer cell 
proliferation, through the IGF-I receptor (Fottner et al., 2001 and Logié et al., 1999).  
The IGF-II overexpression is the result of changes at the 11p15 locus (Gicquel et al., 1994; 
Gicquel et al., 1997). LOH at 11p15 is much more frequent in ACC (78,5%)  than in ACT 
(9,5%) (Gicquel et al., 2001). It is associated with a higher risk of tumor recurrence, and 
correlates with Weiss score. Thus, according to Gicquel and colleagues, 11p15 alterations 
could be used as a biological marker for confirming ACC malignancy after surgical removal 
of the tumor (Gicquel et al., 2001). 
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The 11p15 region is organized in a telomeric domain containing the IGF-II gene and H19 
and a centromeric domain including the CDKN1C (p57kip2) (DeChiara et al., 1991; Hao et 
al., 1993; Lee et al., 1995; Matsuoka et al., 1995). Genetic and epigenetic changes in the 
imprinted 11p15 region resulting in low p57kip2 and H19 and elevated IGF2 mRNA 
expression levels have been reported in sporadic ACCs (Gicquel et al., 1994; Gicquel et al., 
1997). The IGF-II system, in the adrenal gland, is responsible for growth-promoting and 
differentiating functions during the fetal period (Mesiano et al., 1993), but its role has 
been largely documented in adrenocortical malignant tumors, also in adult patients 
(Gicquel et al., 2001). In fact, several studies have been successful in showing the strong 
overexpression of IGF-II in malignant adrenocortical tumors (in approximately 90%of the 
cases) (Boulle et al., 1998; Gicquel et al., 1994; Gicquel et al., 1997; Gicquel et al., 2001; 
Ilvesmaki et al., 1993a).  
Inactivating mutations of the TP53 gene located at the 17p13 locus are another genetic 
alteration that is frequently encountered in ACC. TP53 is one of the most relevant tumor 
suppressor genes, frequently mutated in human cancers. The TP53 mutations are 
thought to happen late in the evolution of sporadic malignant adrenocortical tumors. 
Mutations in the exons 5-8 are found more frequently in ACC than in ACT (Hollstein et 
al., 1991; Reincke et al., 1994). The germline mutations in TP53 have been observed in 50-
80% of children diagnosed with sporadic ACC (Libé & Bertherat, 2005; Wagner et al., 
1994; Varley et al., 1999). In southern Brazil where the prevalence of ACC in children is 
10 times greater than in the rest of the world, there is a particular mutation at exon 10 of 
TP53 (Arginine 337 Histidine) in most of the cases (Ribeiro et al., 2001; Latronico et al., 
2001).  
Considering TP 53 gene mutations in sporadic ACC in adults, its frequency has been 
reported in different proportions in diverse studies ranging from 25% to 70%. (Ohgaki et al., 
1993; Reincke et al., 1994; Barzon et al., 2001; Lin et al., 1994) Loss of Heterozigoty (LOH) at 
17p13 was reported in 95% of ACC and only in 30% of ACT (Gicquel et al., 2001) and 
therefore this can also be used as a marker of malignancy.  
Other reported molecular studies have suggested that genetic alterations of the Wnt 
signaling pathway may also be associated with the development of adrenocortical 
tumors. In fact the activation of the Wnt signaling pathway is the most prevalent defect 
in adrenocortical tumorigenesis particularly due to the fact that it is not only present in 
malignant lesions but in benign adrenocortical adenomas as well (Tissier et al., 2005). 
The Wnt family includes a group of growth factors involved in developmental and 
homeostatic processes. Some regulatory genes in this pathway (including the down 
regulators of ǃ-catenin, GSK3, Axin and APC, and ǃ-catenin itself) can be mutated in 
primary human cancers (Polakis et al., 2000). In all of them the common denominator is 
the activation of gene transcription by ǃ-catenin (via the transcription factors TCF and 
LEF).  
ǃ-catenin has a dual function in the cell: cell-adhesion (conjugated with E-cadherin) and 
transcriptional regulation. When the regulators of ǃ-catenin are down-regulated the 
transcriptional function is increased and the adhesion is reduced and both of these 
alterations lead to the progression of malignancies (Brembeck et al., 2006). 
Genetic alterations in the Wnt pathway conducting to ǃ-catenin accumulation in the 
cytoplasm have been correlated with the pathogenesis of different types of cancer 
www.intechopen.com
 Adrenal Cortex Tumors and Hyperplasias 
 
317 
(Gordon & Nusse, 2006). Curiously, in adrenocortical tumors, the accumulation of ǃ-
catenin has been found in both benign and malignant situations although with a slightly 
higher prevalence in adrenal cortex cancer (Tissier et al., 2005). It is a fact that ǃ-catenin 
mutations are the most frequent genetic defects reported in adrenocortical adenomas and 
in these benign ACT it is mostly the non-secretory adenomas that have these mutations 
(Tissier et al., 2005). According to that study, abnormal cytoplasmic and/or nuclear 
accumulation of ǃ-catenin was found in 38% of the adrenocortical adenomas (ACA) and 
in 77% of the ACC, but mutations in the ǃ-catenin gene were found with similar 
frequencies of in both ACA and ACC (27% vs. 31%) (Tissier et al., 2005).  These somewhat 
opposite results suggest that other components of the Wnt signaling pathway, such as the 
adenomatous polyposis coli (APC) or axin, may be contributing to the pathogenesis of 
ACC (Tissier et al., 2005).   
2.2 Adrenal cortex cancer – Diagnosis and clinical presentation 
Adrenocortical tumors can be classified as functional, when their hormonal secretions 
result in clinical consequences, or nonfunctional tumors, when they do not secrete 
hormones in a sufficient level to produce clinical consequences. About 50 to 60% of the 
adrenocortical carcinomas are functional, therefore, associated with hormonal secretion 
(Ng & Libertino, 2003; Allolio & Fassnacht, 2006). The most frequent presentation among 
adults is the Cushing’s syndrome alone (45%) or the association of Cushing’s syndrome 
with a virilization syndrome, with over-production of both glucocorticoids and 
androgens (25%) (Ng & Libertino, 2003; Wajchenberg et al., 2000). Other forms of 
functional tumors include the virilization syndrome alone and the feminization 
syndrome. Thus, signs and symptoms of adrenocortical tumors may vary significantly 
according to their origin and depending on the type of hormones that are released. 
Cortisol excess can be associated to symptoms such as centripetal obesity, protein 
wasting with skin thinning and striae, muscle atrophy (myopathy), osteoporosis, 
psychiatric disturbances, impaired defense against infections, diabetes, hypertension and 
gonadal dysfunction in men and women. In the case of aggressive malignant ACC 
weight loss may be observed.  Androgen over-secretion is associated with various 
manifestations in women like hirsutism, menstrual abnormalities, infertility and 
eventually virilization, while excess of estrogen, although not so common, can present as 
gynecomastia in men. It is most important to characterize the adrenocortical carcinoma’s 
secretory profile in order to establish its origin and better guide its treatment and follow-
up (Libé et al., 2007). 
Due to the elevated possibility of non-specific symptoms, both symptomatic and 
apparently asymptomatic patients should be evaluated. 
According to the European Network for the Study of Adrenal Tumors (ENSAT), both 
should be studied with the following laboratory tests to determine the secretory activity of 
the tumor (Fassnacht & Allolio, 2009):  
 fasting blood glucose and HbA1c; 
 serum potassium;  
 adrenal androgens (DHEA-s, androstenedione, testosterone, 17-OH progesterone); 
 serum estradiol in men and postmenopausal women; 
 cortisol and adrenocorticotropic hormone (ACTH) both fasting and around midnight 
(in the serum or in the saliva);  
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 fasting serum cortisol at 8 AM following a 1 mg dose of dexamethasone on the previous 
day at bedtime; 
 24-hour urinary free cortisol. 
After careful hormonal assessment, imaging studies, by means of computerized tomography 
(CT), magnetic resonance imaging (MRI) or 18 F-fluorodeoxyglucose positron emission 
tomography (FDG-PET), are the next essential exams both to localize and delimitate the 
tumor and to distinguish benign adenomas from adrenocortical carcinomas (Boland et al., 
1998; Hamrahian et al., 2005; Szolaret al., 2005; Caoili et al., 2002; Groussin et al., 2009; Minn 
et al., 2004; Metser et al., 2006 Wajchenberg et al., 2000). Despite sometimes being considered 
a controversial position, several studies have shown that the size and the appearance of the 
tumor remains one of the best indicators of malignancy (most molecular studies add only a 
little to the accuracy of malignancy identification by the mere determination of tumor size). 
In a study from the National Italian Study Group on Adrenal Tumors including 887 patients 
with adrenal incidentalomas, adrenocortical carcinomas were significantly associated with 
mass size, with 90% being more than 4 cm in diameter when discovered (Angeli et al., 1997). 
According, to a study by Sturgeon and colleagues at the University of California (San 
Francisco)  including 457 ACC cases, a size of  ≥4 cm makes the likelihood of malignancy 
double (to 10%) while in tumors ≥8 cm it gets more than ninefold higher (47%) (Sturgeon et 
al., 2006).  
However, because of the growing evidence of adrenocortical cancers diagnosed with a 
diameter between 4 and 6 cm (Sturgeon et al., 2006; Grumbach et al., 2003; Herrera et al., 
1991; Mantero et al., 2000) and since it seems evident that during their early stages of 
development, carcinomas have to be small, it becomes clear that surgical intervention would 
be most beneficial the smaller and more localized the tumor would be.  
Overall, prognosis does improve for patients with smaller adrenocortical tumors at the 
time of diagnosis. In a retrospective review of 62 ACC cases (Henley et al., 1983) patients 
with stages I to III lesions who underwent curative resections had significantly longer 
survival rates. In another study done by Fassnacht and colleagues, the five year  
survival significantly improved (82% vs 18%) for patients with smaller tumors (stages I 
and II, confined to the adrenal gland) vs. metastatic disease, stage IV (Fassnacht et al., 
2009).  
As general rules, one could say that the prognosis is better in the case of young children, 
in smaller and localized tumors specially if nonfunctioning and in which a complete 
resection can be achieved. 
Despite the importance of evaluating an adrenal mass size and appearance, this should 
not be the only parameter guiding diagnosis and posterior treatment, since radiographic 
features are often of strong predictive value (Dunnick et al., 1996). MRI and CT images 
may in fact be useful in helping to define what will be the histological type of the adrenal 
tumor: 
On unenhanced CT scanning, the measurements of Hounsfield units (HU) are of great 
value in differentiating malignant from benign adrenocortical tumors. The Hounsfield 
scale is a semi-quantitative method of measuring x-ray attenuation. Despite the fact that 
around 30% of adenomas do not contain large amounts of lipid, being indistinguishable 
from non-adenomas, adrenal masses with < 10 HU on unenhanced CT are almost 
certainly benign tumors (Grumbach et al., 2003). Therefore, this seems to be the consensus 
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cut-off for distinguishing adrenocortical carcinomas from benign adrenal tumors, 
according to several studies (Boland et al., 1998; Hamrahian et al., 2005). However, in 
those cases of benign tumors with poor intracytoplasmatic lipid concentration a better 
discrimination can be obtained by searching for a delayed contrast clearance in contrast-
enhanced CT. In this case, tumors measuring > 10HU in a unenhanced CT,  that show a 
contrast  washout of less than 50% after 10- to 15-min of contrast-enhanced CT and also a 
delayed attenuation of more than 35HU, are suspicious for malignancy (Szolar et al., 2005; 
Caoili et al., 2002). 
The use of MRI for differentiating benign and malignant adrenocortical tumors is equally 
effective to CT scan. But since MRI is more expensive and less standardized, CT scan 
remains the primary adrenal imaging procedure, 
The utilization of the PET scanning with fluorodeoxyglucose (FDG) has been successful in 
identifying unilateral adrenal tumors with higher suspicion for malignancy, due to the 
greater reported uptake of FDG by malignant tumors compared to the benign adrenocortical 
tumors (Groussin et al., 2009; Maurea et al. 2001; Minn et al., 2004). The use of integrated 
PET-CT can further improve the capacity to distinguish between malignant and benign 
tumors by increasing the quality of the image. This improvement is also due to the 
combination of CT attenuation measurements with the intensity of FDG uptake, as 
described by the standardized uptake value (SUV) for the adrenal lesion (Metser et al., 2006; 
Caoili et al., 2007).  
In what concerns fine-needle aspiration biopsy (FNA) one must stress that usually it is 
not successful in distinguishing between malignant and benign tumors and there are 
doubts about the risk of disseminating a carcinoma through the abdominal cavity; it can 
however be of some utility in differentiating an adrenal tumor from a metastasis to the 
adrenal and in evaluating staging for a known cancer (Jhala et al., 2004; Kocijancic et al., 
2004). 
2.3 Adrenal cortex cancer staging 
The first staging system published by the World Health Organization (WHO) dates from 
in 2004 (DeLellis, 2004), and was based on different staging systems, such as the Sullivan 
modification of the Macfarlane system (Sullivan, 1978). The AJCC (American Joint 
Committee on Cancer)/UICC (International Union Against Cancer) developed a TNM 
staging system with the same definitions for the first time in 2009, being published on 
the AJCC/UICC Cancer Staging Manual, Seventh Edition. A simplified classification 
system was recently proposed by the European network ENSAT in which stage III 
includes cases with lymph nodes metastasis, infiltration of surrounding tissues and 
venous tumor thrombosis and stage IV only cases with distant metastases (Fassnacht et 
al., 2009).  
Tumor clinical staging is most dependent of clinical examination and radiographic imaging 
in order to evaluate the size of the primary tumor and the extent of local and distant disease. 
Since disease-free and overall survival rates seem to be strongly related with tumor staging, 
resection of the primary tumor and examination of local extension of the disease and 
regional lymph nodes involvement should be performed for a better pathologic tumor 
staging.  
The following table describes the AJCC/UICC anatomic stages and prognostic groups: 
www.intechopen.com
  
Contemporary Aspects of Endocrinology 
 
320 
Stage T N M Description 
Stage I T1 N0 M0 
Tumor 5 cm or less in greatest dimension, no 
extra-adrenal invasion. 
Stage II T2 N0 M0 
Tumor greater than 5 cm, no extra-adrenal 
invasion. 
Stage III 
T1 N1 M0 
Tumor 5 cm or less in greatest dimension, no 
extra-adrenal invasion but with metastasis in 
regional lymph node(s). 
T2 N1 M0 
Tumor greater than 5 cm, no extra-adrenal 
invasion but with metastasis in regional 
lymph node(s). 
T3 N0 M0 
Tumor of any size with local invasion, but 
not invading adjacent organs*. 
Stage IV 
T3 N1 M0 
Tumor of any size with local invasion, but 
not invading adjacent organs* plus 
metastasis in regional lymph node(s). 
T4 N0 M0 
Tumor of any size with invasion of adjacent 
organs*. 
T4 N1 M0 
Tumor of any size with invasion of adjacent 
organs* plus metastasis in regional lymph node(s). 
Any T Any N M1 
Tumor of any size and with or without 
invasion of adjacent organs and lymph 
nodes, but with distant metastases. 
Adapted from  Edge, SB., Byrd, DR., Compton, CC., Fritz, AG., Greene, FL., Trotti, A. (Eds.). (2010). 
AJCC Cancer Staging Manual, 7th Ed. Springer, Chicago. 
*Adjacent organs include kidney, diaphragm, great vessels, pancreas, spleen and liver. 
Table 2. AJCC/UICC anatomic stages and prognostic groups 
2.4 Adrenal cortex cancer treatment  
For being a very rare and aggressive carcinoma the prognosis for patients with adrenocortical 
cancer is poor, also due to usually not being diagnosed in the early stages of the disease (Ng & 
Libertino, 2003; Harrison et al., 1999). Its rarity is one of the main reasons for the lack of robust 
clinical studies on the most efficacious treatments (Decker et al., 1991; Bukowski et al., 1993; 
Khan et al., 2000). Several studies and clinical trials, however, have shown that this trend in 
prognosis is changing and in fact patients with this type of carcinoma are living longer as 
progresses are being made in its treatment (Berruti et al., 2005; Adam et al., 2006; Allolio et al., 
2004; Terzolo et al., 2007; van Ditzhuijsen et al, 2007; Fassnacht et al., 2011). 
Currently, the only potentially curative treatment for adrenal cortex carcinomas is total 
resection of the tumor at the time of initial evaluation (Allolio et al., 2006; Dackiw et al., 
2001). However, in a study of Haak and colleagues with 96 patients, the overall five-year 
survival rate after total resection was only 49% (Haak et al., 1994). This happens probably 
due to the presence of hidden micrometastases that will only become apparent some months 
to years later (Allolio & Fassnacht, 2006; Stojadinovic et al., 2002). In fact, many patients may 
develop distant metastases two or more years after the diagnosis date (Abiven et al., 2006).  
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Therefore, surgery in these patients must be as extensive as possible, with lymphadenectomy 
associated. One should be very careful to avoid capsular damage and the spill of malignant 
cells that may result in the development of metastasis (Terzolo et al., 2007; van Ditzhuijsen et 
al., 2007).  Nowadays, open adrenalectomy is the most consensual operation type, since 
laparoscopy is associated with greater risk of malignant cells spread and therefore higher risk 
of recurrence or dissemination (Schteingart et al., 2005; Gonzalez et al., 2005; Cobb et al., 2005).  
Studies have also shown that whenever total resection is not possible, maximal debulking is 
associated with a decrease in excess of hormone production and with better overall survival 
when compared with non-surgical treatments (Ng & Libertino, 2003; Luton, et al., 1990).  
Whenever surgery is not feasible or is unable to completely remove the tumor, mitotane 
(Lysodren), an adrenocorticolytic drug, was shown to be effective, either as a primary 
therapy or as an adjuvant therapy (Henley et al., 1983; Dackiw et al., 2001; Berruti et al., 
2005; Terzolo et al., 2007; Luton et al 1990; Hahner & Fassnacht, 2005). Mitotane has a 
specific effect on adrenal cells resulting in their lysis (Hahner & Fassnacht, 2005).  
As a primary treatment for unresectable tumors, mitotane is especially beneficial in 
improvement of symptoms associated with hypercortisolism. However this benefit tends to 
last for short periods of time, and is associated to inconsistent survival rates (Henley et al., 
1983; Baudin et al., 2001).  
In what concerns the adjuvant use of mitotane therapy, its benefits have been questioned 
mainly due to the lack of data from controlled clinical trials and even from large prospective 
studies with consistent assessments of dosing and tumor variability (Kendrick et al., 2001; 
Kopf et al., 2001). Despite the lack of robust data, several retrospective analyses have reported 
higher recurrence-free survival when compared to control groups and tumor regression rates 
of around 30% also being associated with a better control of hormone excess (Allolio & 
Fassnacht, 2006; Terzolo et al., 2007). Treatment with mitotane has especially good results in 
patients previously submitted to tumor resection, who begun therapy right after surgery and 
who are submitted to regular monitoring of mitotane plasma levels (Daffara et al., 2008).  
When considering recurrent or advanced adrenocortical cancer, aggressive resection of local 
or distant disease is still considered to be an effective therapy method capable of increasing 
overall survival (Schteingart et al., 1982; Meyer et al., 2004). However, in these cases the use 
of cytotoxic drugs such as mitotane alone or in combination with other chemotherapeutic 
agents has to be utilized (Allolio & Fassnacht, 2006).  
Mitotane is recommended even in patients with unresectable advanced disease, since 
several studies have reported the effectiveness of this drug in producing objective 
improvements in the majority of treated patients, despite its low impact on survival. 
Moreover, it has been demonstrated that cytotoxic activity of chemotherapeutic agents is 
increased when combined with mitotane in human adrenal carcinoma cells in vitro 
(Bukowski et al., 1993; Abraham et al., 2002). Despite the modest results found in the few 
prospective trials published until now, the combination of mitotane with different 
chemotherapeutic regimens resulted in overall response rates varying between 14 to 49% 
(Berruti et al., 2005; Khan et al., 2000; Abraham et al., 2002; Bonacci et al., 1998).  
Other regimens of chemotherapy without mitotane have been also evaluated in a few 
clinical trials but showed modest response rates, revealing the need for the development of 
more and better drugs and well-designed prospective trials (Schlumberger et al., 1988; 
Quinkler et al., 2008; Khan et al., 2004).  
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One must be conscious that progresses in this cancer treatment are limited and slow. More 
clinical trials and large prospective studies are necessary to better support physicians’ 
choices of treatment. An example of those trials was the recently concluded “First 
International Randomized trial in locally advanced and Metastatic Adrenocortical 
Carcinoma Treatment” (FIRM-ACT), an international clinical study comparing the efficacy 
of etoposide, doxorubicin and cisplatin (EDP) plus mitotane versus streptozotocin plus 
mitotane in patients with metastatic adrenocortical cancer. This sufficiently large 
prospective study gave support to the use of the first therapeutic combination 
(EDP+mitotane) in these conditions (Fassnacht et al., 2011).  
The use of radiation therapy or radiofrequency ablation are the least studied hypothesis. 
They are mainly beneficial in patients with unresectable local tumors with local symptoms 
or symptomatic metastasis (Schteingart et al., 2005; Polat et al., 2009; Magee et al., 1987). 
Their impact in patients’ survival is still unknown and needs further investigation (Wood et 
al., 2003; Mayo-Smith et al., 2004). 
In the future one may expect that the understanding of the specific molecular alterations in 
these malignant cells can identify suitable therapeutical targets that may significantly 
improve the prognosis for these patients.  
3. Primary hyperaldosteronism/Conn’s syndrome 
The synthesis of aldosterone by the adrenal glands occurs in the zona glomerulosa. The major 
conditions for the production of this hormone such as the low concentration of 17-alpha-
hydroxylase and the ability to add an hydroxyl group at the 18-carbon position and its 
subsequent oxidation to an aldehyde, only occur in the zona glomerulosa and this processing 
is mediated by a single multifunctional cytochrome P450 - CYP11B2 or Aldo Synthase 
(White et al., 1987; White, 1994; Ulick et al., 1992; Holland & Carr, 1993). 
The aldosterone-producing adenoma was first described by Conn in 1954 (Conn, 1955; 
Young, 2007a), who also established for the first time the relationship between adrenal 
aldosterone-producing tumors, hypertension, and hypokalemia (Gittler & Fajans, 1995). In 
addition to the aldosterone-producing adenoma (APA), other subtypes of primary 
aldosteronism (PA) have been described over the subsequent four decades (Conn, 1955; 
Conn, 1964; Gitler & Fajans, 1995; Young, 2007a; Stowasser, 2009). The most common is the 
bilateral idiopathic hyperaldosteronism (IHA) which represent approximately 70% of all PA 
cases (while APA, approximately 30%). Other forms include unilateral hyperplasia or 
primary adrenal hyperplasia (caused by hyperplasia of the zona glomerulosa of only one 
adrenal gland), familial hyperaldosteronism type I (glucocorticoid-remediable 
aldosteronism - GRA) caused by the existence of an hybrid gene composed of the CYP11B1 
promoter and CYP11B2 gene in which aldosterone is produced in response to ACTH and 
hence responds to glucocorticoid mediated suppression of ACTH, familial 
hyperaldosteronism type II (the familial occurrence of aldosterone-producing adenoma or 
bilateral idiopathic hyperplasia or both), and also the familial or sporadic occurrence of APA 
due to a mutation in the gene of the K+ channel (KCNJ5) (Choi et al., 2011).  
Finally, in spite of being very rare, pure aldosterone-producing adrenocortical carcinomas 
and ectopic aldosterone-secreting tumors (e.g. neoplasms in the ovary or kidney) may also 
occur. 
The screening of PA is done by the demonstration of an elevated aldosterone level (> 15 
ng/dl) together with the suppression of Plasma Renin Activity (PRA), translated in an 
www.intechopen.com
 Adrenal Cortex Tumors and Hyperplasias 
 
323 
increased Aldosterone (in ng/dl)/PRA (in ng/ml/h) ratio above 20 or 40 (accordingly to the 
desired sensitivity).  
Then a confirmatory test is needed and this can be done by one of the following tests:  
 fludrocortisone suppression test 
 oral salt load  
 saline infusion test  
 Captopril test 
Since these tumors are generally very small, CT scan has a low sensitivity to localize them, 
and the fact that in people above 40 to 50 years of age, the prevalence of incidentalomas is 
high makes its specificity also decrease. Therefore the gold standard for a correct diagnosis 
of APA is Adrenal Venous Sampling in spite of the fact that it is an invasive method with a 
good success rate only in the hands of experienced radiologists. 
During the past two decades it has become increasingly recognized that primary 
aldosteronism is much more common than previously thought. It is currently acknowledged 
that primary aldosteronism accounts for up to 5–10% of hypertensive patients, correlating 
with the severity of hypertension and going up to 20% in cases of resistant hypertension (i.e 
one that does not respond to 3-drug-regimen).  
The clinical features of PA are mostly determined by the renal actions of aldosterone. Its 
diagnosis is more frequently made in patients who are in the third to sixth decades of life, 
with resistant hypertension, accompanied by marked hypokalemia, possibly muscle 
weakness and cramping, headaches, palpitations, polydipsia, polyuria, nocturia, or a 
combination of these. There is, however, generally a characteristic lack of edema!  
Hypokalemia, once the most important “screening” method for PA is observed less and less 
frequently both due to the sodium restriction that most doctors recommend to their patients 
with high blood pressure and also to the higher prevalence of BAH vs APA observed in the 
more recent series. 
Patients’ elevated blood pressure is a major clinical finding in PA (Mattsson & Young, 2006; 
Young, 2007a). However, PA is rarely associated with malignant hypertension (Zarifis et al., 
1996). In a study of Blumenfeld and colleagues, the mean blood pressure was 184/112 
mmHg in patients with an adrenal adenoma and 161/105 mmHg in patients diagnosed with 
bilateral hyperplasia (Blumenfeld et al., 1994). One important and special feature associated 
with PA hypertension is the failure to achieve the goal blood pressure (BP) despite a 
complete adherence to a multi-drug regimen of treatment.  
It was also clearly demonstrated that aldosterone excess has direct adverse cardiovascular 
consequences that go well beyond the risks associated with this type of hypertension 
(Stowasser, 2009). Aldosterone is responsible for the development of myocardial fibrosis 
aggravating the prognosis post myocardial infarct (MI) and in congestive heart failure (CHF).  
Cardiovascular risk factors seem to be more severe with PA, since when matched for age, 
blood pressure and the duration of hypertension, these patients have greater left ventricular 
mass measurements when compared to patients with other types of hypertension, including 
essential hypertension, pheochromocytoma, and Cushing's syndrome (Milliez et al., 2005; 
Tanabe et al., 1997). Also, in a case–control study of 124 patients with PA and 465 patients 
with essential hypertension, matched for age, sex, and systolic and diastolic blood pressure, 
it was found that patients presenting with either APA or bilateral hyperplasia had a 
significantly higher rate of cardiovascular events (e.g. stroke, atrial fibrillation and 
myocardial infarction) than the matched essential hypertension patients (Milliez et al., 2005). 
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Furthermore, some particular renal effects may be also experienced by PA patients, 
independently of their systemic hypertension. Several reports have shown that glomerular 
filtration rate (GFR) and urinary albumin excretion may be increased in these patients; 
however these changes appear to be largely reversible after appropriate treatment.  
Adrenalectomy increased the serum creatinine and decreased the mean GFR. Treatment 
with spironolactone resulted in a similar decline in GFR. Thus, surgical cure or 
mineralocorticoid receptor blockade reverse the hyperfiltration state and unmask the 
underlying renal insufficiency (Stowasser, 2009). 
One final point to be stressed in relation to PA is that generally APA should be treated 
surgically while bilateral adrenal hyperplasias are better treated medically with 
mineralocorticoid inhibition by means of spironolactone, eplerenone or amiloride. 
Nevertheless, even APAs, specially the small ones, may also be treated appropriately with 
these drugs and hence, the choice should always be given to the patients. 
4. Androgen-secreting adrenal cortex tumors 
Androgen-secreting adrenal cortex tumors are rare tumors, accounting for only 0.2% of the 
causes of androgen excess (Azziz et al., 2004; Carmina et al., 2006). Androgen over-secretion 
results in the development of androgenic features in affected women, with the development 
of hirsutism, androgenic alopecia, acne, ovulatory dysfunction, and, if the oversecretion is 
extreme or prolonged, even virilization may ensue (Wajchenberg et al., 2000; Azziz et al., 
2004).   
Despite the fact that benign androgen-secreting adrenal tumors have been described, the 
finding of androgen secretion by an ACT is considered to be highly suggestive of 
malignancy. The presence of a virilizing adrenocortical carcinoma can be suggested by very 
high testosterone levels and the failure of androgen suppression in response to 
glucocorticoid administration (Kaltsas et al., 2003; Waggoner et al., 1999; Derksen et al., 
1994). In a report of 21 women with androgen-secreting tumors, serum testosterone levels 
were 2.6-fold higher in the women with malignant tumors (n=10) than in women with 
benign tumors (n=11) (Moreno et al., 2004).  
Benign cortisol-secreting adenomas can also produce small amounts of androgens, but the 
serum androgen levels are usually not elevated (Kamenicky et al., 2007).  
Considering its elevated probability of malignancy it is of great importance to identify 
patients with this type of rare carcinomas among women with androgen excess, due to 
its life-threatening potential (Wajchenberg et al., 2000). Despite several authors having 
considered that a clinical presentation with rapidly progressive virilization was 
sufficient to identify patients requiring a more extensive investigation (Kettel, 1989), it is 
consensual that some androgen-secreting adrenocortical tumors may produce only 
moderate levels of androgens and have a rather indolent presentation (Rosenfield , 2005; 
Kaltsas et al., 2003).  
It should also be noticed that androgen-secreting tumors in men same as estrogen secreting 
tumors in women, may not result in clinically significant syndromes, and both can be 
erroneously considered as non-functioning, delaying their treatment. If one doesn’t apply an 
extensive analytical protocol to nonfunctioning adrenocortical tumors, only the 
development of mass effects or the occurrence of metastases would lead to their recognition 
as malignant. 
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5. Estrogen-secreting adrenal cortex tumors 
Estrogen-secreting adrenal cortex tumors correspond to a very rare type of tumors 
characterized by the over-production of estrogens (estrone or estradiol). The over- secretion 
of these hormones may cause precocious puberty with very early menarche in girls and 
more often sex-reversal characteristics in men (feminizing symptoms) (Advani et al., 2010). 
The feminizing symptoms, such as the characteristic gynecomastia, are associated with the 
expression of the cytochrome P450 aromatase (aromatase) in adrenocortical cells. Normally, 
aromatase catalyses the conversion of C19 steroids into estrogens in tissues such as the 
ovarian follicles’ granulosa layer and the adipose tissue, whereas normal adrenal tissues 
have no detectable aromatase activity (Watanabe & Nakajin, 2004).  
6. Cushing’s syndrome 
The Cushing’s syndrome was first described by Harvey Cushing in 1932, and can be caused 
by several mechanisms associated with increased levels of cortisol in the blood. The 
diagnosis of Cushing’s syndrome is determined through biochemical tests, since the 
presence of suggestive symptoms and signs are not enough to sustain it. In fact none of its 
symptoms is pathognomonic and most of them are non-specific such as obesity, 
hypertension and increased cardiovascular risk, menstrual irregularity and infertility, 
osteoporosis and glucose intolerance. It can also cause some form of psychological distress, 
going from impaired quality of life to depression and even psychosis. It should always be 
borne in mind, however, that if left untreated, Cushing’s syndrome has a 5 fold excess 
mortality.  
The high levels of cortisol in the blood can be caused not only by adrenocortical tumors but 
also by adrenocorticotropic hormone (ACTH) or  corticotropin-releasing hormone (CRH) 
hyperproduction, as well as by the excessive intake of glucocorticoid drugs. This is even one 
of the most frequent causes of Cushing’s syndrome (Iatrogenic Cushing’s). In the study of a 
Cushing’s syndrome case these situations need to be excluded (Weber SL., 1997; Hughes et 
al., 1996; Quddusi et al., 1998). Moreover, special attention is also required for other 
disorders causing hypercortisolism-related symptoms and sometimes also exhibiting mild 
to moderate elevations of plasma cortisol, known as pseudo-Cushing’s syndrome. The 
pseudo-Cushing’s syndromes may include: 
 Patients who are physically stressed (e.g. severe bacterial infections) (Liddle , 1960); 
 Patients with severe obesity, especially visceral obesity or polycystic ovary syndrome 
(Liddle, 1960); 
 Patients with psychological stress (major depressive disorder and severe melancholic 
syndromes) (Gold et al ., 1986); 
 Rarely, also patients with chronic alcoholism (Kirkman & Nelson, 1988). 
The difficulties normally met in Cushing’s syndrome diagnostic process are well translated 
by the fact that patients normally express some signs and symptoms of the syndrome, 2 
years before a confirmation of diagnosis can be reached.  After raising the suspicion by the 
observation of a patient with central (truncal) obesity plus hypertension, in many cases 
accompanied by a typical cushingoid facies (round, plethoric face), the most specific signs 
are the presence of thin skin, easy bruising and proximal myopathy. However, to avoid 
mistakes in diagnosing Cushing’s syndrome due to all of the different conditions that might 
imitate its signs and symptoms, initial diagnostic tests for hypercortisolism must be highly 
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sensitive. According to the evidence-based 2008 Endocrine Society Clinical Guidelines the 
first-line tests for this syndrome should be the late night salivary cortisol, the 24h urinary 
cortisol, or the low-dose dexamethasone suppression test (either the 1 mg, overnight or the 
2mg/day, 48h dexamethasone suppression tests). To establish the diagnosis of Cushing’s 
syndrome the following criteria should be met (Nieman et al., 2008): 
 At least two of the first-line tests must be abnormal and conservative criteria should be 
used to interpret it to maximize sensitivity; for instance, in a patient with a symptomatic 
Cushing’s syndrome, the cortisol cutoff level to be considered as un-suppressed after 
the Dexamethasone test should be >1.8  µg/dl (while in the case of incidentalomas 
studied to exclude subclinical Cushing’s syndrome, specificity should be the main 
criterion and so the cutoff level should be >5 µg /dl). 
 Urinary and salivary cortisol measurements should be obtained at least twice; 
 The urinary cortisol excretion should be unequivocally increased (threefold above the 
upper limit of normal for the assay), or the diagnosis of Cushing's syndrome is 
uncertain and other tests should be performed; 
 The patient should undergo additional evaluation if the test results are discordant or 
only slightly abnormal; 
 If test results are normal, the patient does not have Cushing's syndrome unless it is 
extremely mild or cyclic. Additional evaluations are not suggested unless symptoms 
progress or cyclic Cushing's syndrome is suspected. 
Cushing’s syndrome is rare (it has an incidence of  up to 3:1.000.000 persons per year) 
(Lindholm et al., 2001). It’s also an intriguing condition both because of its complex 
diagnostic protocol and the demand for a correct treatment to avoid its devastating 
complications that can even conduct to death if left untreated. After diagnosing the 
hypercortisolism, it is important to determine its cause (Table 3) to better chose the 
appropriate treatment. It is a disease whose patients should be sent to a major hospital 
where multidisciplinary and well experienced teams will be available. 
 
Diagnosis Percentage of Patients (%) 
ACTH-dependent Cushing's syndrome 
Cushing’s disease 68 
Ectopic ACTH syndrome 12 
Ectopic CRH syndrome < 1 
ACTH-independent Cushing’s syndrome 
Adrenal adenoma 10 
Adrenal carcinoma 8 
Micronodular hyperplasia 1 
Macronodular hyperplasia < 1 
Pseudo-Cushing’s syndrome 
Major depressive disorder 1 
Alcoholism < 1 
Table 3. Frequency of causes of Cushing’s syndrome 
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One of the most important, and therefore the initial, phase of determining Cushing’s 
syndrome’s etiology is to determine if the hypercortisolism is ACTH-dependent or ACTH 
independent. The ACTH-dependent hypercortisolism is normally due to a pituitary (or 
less frequently non-pituitary) ACTH secreting tumor, while ACTH-independent 
hypercortisolism is usually due to an adrenal tumor or hyperplasia. The preferred test is 
naturally the measurement of plasma ACTH. Usually a low plasma ACTH concentration 
of <5 pg/mL (1.1 pmol/L) in a hypercortisolemic patient is evidence of ACTH-
independent disease (Invitti et al., 1999), while if the plasma ACTH concentration is above 
15 pg/mL (3.3 pmol/L) it can be assumed that cortisol secretion is ACTH-dependent. 
Despite values between 5 and 15 pg/mL (1.1 to 3.3 pmol/L) being less definitive they 
normally indicate the hypercortisolism is ACTH-dependent. However, it is 
recommendable to perform a CRH stimulation test in these patients to confirm that 
hypothesis. 
In the presence of an ACTH-independent Cushing's syndrome, it is important to proceed 
with a thin-section CT imaging of the adrenal glands, to determine its cause. When CT 
imaging suggests a suspicious lesion (for instance with large size) further investigation will 
be required to distinguish between the malignant ACC and benign ACT. The presence of 
bilateral disease on the other hand implies the distinction between, for instance, a bilateral 
tumor and bilateral macronodular adrenal hyperplasia. 
 
 
Fig. 2. Cushing syndrome 
Unilateral adenomas causing Cushing’s syndrome should be surgically removed as they 
imply a very significant increase in morbidity and mortality, which is due to cardiovascular 
diseases or infections. 
For the great majority of ACTH-dependent Cushing’s syndrome patients, the cause of the 
hypercortisolism is a pituitary corticotroph adenoma (Cushing’s disease). Even so, 
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patients with ACTH-dependent disease should undergo non-invasive tests such as the 
high-dose dexamethasone suppression test and the CRH stimulation test, to confirm the 
presence of Cushing’s disease. It is also important to exclude extrapituitary (ectopic) 
sources of ACTH. 
7. Subclinical Cushing’s syndrome 
The "subclinical" Cushing's syndrome (SCS) refers to autonomous cortisol production that is 
insufficient to generate the typical, clinically recognizable, combination of symptoms. The 
prevalence of overt Cushing’s syndrome caused by an adrenal adenoma in the general 
population is lower than the prevalence of subclinical Cushing’s syndrome in patients with 
clinically non-functioning adrenal adenoma (Ross, 1994).  
Patients with SCS have an adrenal mass usually detected incidentally (an incidentaloma) 
and normally do not show any of the clinical manifestation of the Cushing’s syndrome 
(Terzolo et al., 2005a). Still, they have some endocrine alterations that allows their 
recognition (Urinary free cortisol > 70 µg /24h; serum cortisol levels after a dexamethasone 
suppression  test >5 µg/dl; morning ACTH levels < 10 pg/ml). According to the Italian 
National survey on 1,004 adrenal incidentalomas (Mantero et al., 2000), of which 92 were 
classified as SCS, the hormonal evaluation showed low baseline secretion of ACTH in 79% 
of the SCS patients, lack of suppressibility of cortisol secretion after 1 mg dexamethasone in 
73%, supra-normal 24-hour urinary cortisol excretion in 75% or disturbed cortisol circadian 
rhythm in 43%. Subclinical Cushing’s syndrome is the most commonly detected 
abnormality in patients with adrenal incidentalomas. 
Most patients with SCS may show one or more of the clinical manifestation of cortisol 
over-secretion, such as arterial hypertension, obesity or diabetes (Terzolo et al., 2000; 
Angeli & Terzolo, 2002). The association between a clinically silent adrenal adenoma and 
some of clinical manifestations of the metabolic syndrome has been studied and is 
considered well proven. In a retrospective study done by Terzolo and colleagues (Terzolo 
et al., 2005b), of 210 such patients, 53.8% had hypertension, 21.4% were obese and 22.4% 
had hyperglycemia.  
8. Incidentalomas 
An adrenal incidentaloma is a mass lesion, usually with 1cm or more in diameter, 
discovered incidentally by radiologic examination (Young, 2007b). In recent years these 
incidentally discovered adrenal masses have been found with increasing frequency due 
to the widespread use of imaging techniques of the abdomen and their prevalence is 
estimated to be around 4% in the general population (Bovio et al., 2006). Several studies 
have been published concerning the prevalence of adrenal incidentalomas. In a series of 
739 autopsies, Hedeland and colleagues (Hedeland et al., 1968) reported the presence of 
adrenal masses in 9% of normotensive patients versus 12% in patients with hypertension. 
In another review including 25 studies (Kloos et al., 1995), the calculated prevalence of 
adrenal incidentaloma was of 6%.  The prevalence of adrenal adenomas increases with 
age from 0.2%in a patient between 20 and 29 years of age to 7% in a patient over 70 years 
of age (Young, 2007; Kloos et al., 1995). It is noteworthy that they are rare under the age 
of 40.  
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Despite the fact that the majority of adrenal incidentalomas are clinically non-hypersecreting 
and benign adrenocortical adenomas (Mansmann et al., 2004), frequently, incidentalomas’ 
series include cases that are cortisol secreting adrenocortical adenomas (5 to 9%) (Mantero et 
al., 2000; Young 2007) or pheochromocytomas (3 to 5%) (Young, 2007; Cawood et al., 2009). 
Of these pheochromocytomas, 50% are normotensive (Motta Ramirez et al., 2005). 
Incidentalomas can also be adrenocortical carcinomas and metastatic carcinomas. In a group 
of 2005 patients with adrenal incidentalomas, almost 5% were adrenocortical carcinomas 
and 2.5% corresponded to other primary carcinomas’metastases (Young, 2000). 
The approach to the evaluation and management of adrenal incidentalomas usually begins 
with taking patients’ clinical history and performing a physical examination, testing for 
signs or symptoms of adrenal hyperfunction or malignant disease, and performing a 
complete hormonal evaluation (Young, 2007; Kudva et al., 2003; Terzolo et al., 2005).  
The probability to find a primary adrenal carcinoma in these cases has to be considered as 
rare, in spite of being dependant on the size of the tumor (above 4 cm the probability of an 
incidentaloma being malignant is 24% (Angeli et al., 1997); however, due to the importance 
of such a situation the initial major concern in evaluating an adrenal incidentaloma is the 
possibility of malignancy, followed by the evaluation of the possibility of metastatic cancer. 
In fact, one should also remember that several types of carcinomas may metastasize to the 
adrenal glands (e.g. lung, kidney, colon, breast, pancreas, liver and stomach).  
Adrenal incidentalomas are bilateral in 10-to 15% of the cases. In these cases the etiology 
will be one of the following: metastases; congenital adrenal hyperplasia; bilateral adenomas, 
bilateral adrenocortical macronodular hyperplasia; bilateral pheochromocytomas; 
hemorrhage, lymphoma; infectious or infiltrative diseases. 
As a main conclusion we would like to stress that it is of crucial importance to evaluate all 
patients with adrenal incidentalomas for the possibility of either subclinical hormonal 
hyper-function, including SCS and  pheochromocytoma, as well as cancer. Table 4 
describes major evaluations and clinical features for differential diagnosis of adrenal 
incidentalomas. 
9. Pediatric adrenal cortex tumors 
The presence and diagnosis of adrenal cortex tumors in children is rare and may occur 
sporadically or as a component of certain hereditary tumour syndromes, such as the Li-
Fraumeni syndrome, the multiple endocrine neoplasia-1 (MEN1), the Beckwith-Wiedemann 
syndrome, the Carney complex, and even in some rare cases of congenital adrenal hyperplasia. 
Its incidence is around 1 to 3 in 10.000.000 except in the southern regions of Brazil where it 
reaches 1 to 3 :1.000.000 (Agrons et al., 1999; Ribeiro et al., 2000, Wasserman et al., 2011).).  
In southern Brazil, these carcinomas are frequently associated with a particular mutation of 
TP53 (namely Arg337His) (Ribeiro et al., 1990). 
Clinical and biological characteristics of adrenocortical tumours are different from those 
observed in other paediatric carcinomas. About 65% of them are diagnosed in children younger 
than 5 years of age (Ribeiro et al., 1990). This age distribution has been demonstrated in several 
reports, including a study of Zerbini and colleagues, with 32 pediatric patients with 
adrenocortical neoplasms, in which the age at diagnosis ranged from 6 months to 19 years 
(median age, 5 years), with a predominant number of patients being 5 years of age and younger 
(Zerbini et al., 1992). In another study of Lefebvre and colleagues, with 42 children with 
adrenocortical neoplasms, two-thirds were younger than 5 years of age (Lefevre et al., 1983).  
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Diagnosis 
Suggestive Clinical 
Features 
Imaging Characteristics 
Adrenocortical 
Adenoma 
May have symptoms 
related to excess 
glucocorticoid, 
mineralocorticoid, 
androgen, or estrogen 
secretion 
 Round or oval, with smooth margins 
 Homogeneous 
 Rare tumor calcification, necrosis or 
hemorrhage 
 Small, usually ≤ 3 cm in diameter 
 Usually solitary, unilateral 
 CT unenhanced attenuation values 
≤10 HU  (25% may have low lipid 
content and hence have attenuation 
values >10%) 
 Not highly vascular 
 Isointense in relation to liver onT1- 
and T2-weighted images in MRI 
 No delay in contrast medium 
washout (ten minutes after 
administration of contrast, an 
absolute contrast medium washout of 
50 % or more) 
Adrenocortical 
carcinoma 
Mass effect symptoms, 
symptoms related to 
excess glucocorticoid, 
mineralocorticoid, 
androgen, or estrogen 
secretion. The size (>4/6 
cm) and the evolution are 
the most important signs 
to raise the suspicion 
 Irregular shape 
 Inhomogeneous density because of 
central areas of low attenuation due to 
tumor necrosis  
 Common tumor calcification 
 Diameter usually >4 cm 
 Unilateral location 
 High unenhanced CT attenuation 
values (>20 HU) 
 Inhomogeneous enhancement on CT 
with intravenous contrast 
 Delay in contrast medium washout 
(ten minutes after administration of 
contrast, an absolute contrast medium 
washout of less than 50 %) 
 Hypo-intensity compared with liver 
on T-1 weighted MRI and high to 
intermediate signal intensity on T-2 
weighted MRI 
 High standardized uptake value 
(SUV) on FDG-PET-CT study 
 Evidence of local invasion or 
metastases. 
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Diagnosis 
Suggestive Clinical 
Features 
Imaging Characteristics 
Pheochromocytoma 
Hypertension, Paroxysmal 
Symptoms (e.g. 
palpitation, diaphoresis, 
headache, pallor, tremor). 
Half of the cases will 
remain undiagnosed! 
Plasma metanephrines 
and 24h urine 
metanephrines are the 
initial screening tests 
 Round or oval, with clear margins 
 Heterogeneous, with cystic areas 
 Usually large 
 Usually solitary, unilateral 
 High unenhanced CT attenuation 
values (>10 HU) (usually >25) 
 Usually vascular 
 Delay in contrast medium washout 
(ten minutes after administration of 
contrast, an absolute contrast medium 
washout of less than 50 percent) but 
may be normal, mimicking the 
adenomas 
 Markedly hyper intense in relation to  
the liver on T2-weighted images, in 
MRI 
 Chemical-shift imaging: Pheos and 
ACC don’t loose signal intensity on 
out-of phase images in comparison 
with in-phase ones, whereas 
adenomas do 
 Hemorrhage and cystic areas 
common 
Metastatic Cancer 
Cancer-specific signs. The 
identification of a primary 
extra-adrenal cancer 
favors this possibility  
 Irregular shape and inhomogeneous 
nature 
 Tendency to be bilateral 
 High unenhanced CT attenuation 
values (>20 HU) and enhancement 
with intravenous contrast on CT 
 Delay in contrast medium washout 
(ten minutes after administration of 
contrast, an absolute contrast medium 
washout of less than 50 percent) 
 Isointense or slightly less intense than 
the liver on T-1 weighted MRI and 
high to intermediate signal intensity 
on T-2 weighted MRI (representing an 
increased water content) 
Adapted from Young WF, Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 
2007a; 356: 601-10 
Table 4. Clinical features and imaging characteristics of adrenal incidentalomas 
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About half of the adrenocortical tumours in children have predisposing constitutional 
genetic factors, and are usually associated with the Li-Fraumeni syndrome or the Beckwith-
Wiedemann syndrome (Li & Fraumeni, 1969a; Wiedemann, 1983; Lynch et al., 1978).   
The Li-Fraumeni syndrome is a cancer-predisposing syndrome that includes breast cancer, 
brain carcinoma, sarcomas, leukaemia and adrenocortical carcinoma (Li & Fraumeni, 1969a; 
Lynch et al., 1978). This syndrome is a rare autosomal dominant condition associated with 
germline mutations of the tumour suppressor gene TP53 on the chromosome 17 (17p13) (Li & 
Fraumeni, 1969b; Li et al., 1998; ). The patient and the affected family members may develop 
different types of tumours (Birch, 1994; Srivastava et al., 1990; Sandrini et al., 1997; Hisada et 
al., 1998).  
On the other side the Beckwith-Wiedemann syndrome, associated with abnormalities 
involving chromosome 11p15, and defined as a growth disorder is sometimes referred to as 
the EMG [exomphalos-macroglossia-gigantism] syndrome. This syndrome is associated 
with an increased risk of benign and malignant tumors of multiple organs (Fraumeni & 
Miller et al., 1967; Wiedemann, 1983), particularly the Wilms tumor of the kidneys and 
adrenocortical carcinoma (Lack, 1997).  
The incidence of adrenocortical carcinomas in children is higher in girls. These pediatric 
carcinomas are hormone secreting tumors more frequently than in adults (90% vs 50%) 
(Michalkiewicz  et al., 2004; Patil et al., 2002; Bonfig et al., 2003). The classic endocrine 
syndromes (namely the virilising and the Cushing’s syndromes) represent the most 
common presentations of adrenocortical carcinomas in this age group (Wilkins, 1948 and 
Ribeiro et al., 2000).  
However in spite of being pathologically malignant these carcinomas have a much better 
prognosis, with many of them becoming cured by the first surgical intervention 
(Michalkiewicz et al., 2004;  Sutter et al., 2006; Wieneke et al., 2003; 27: Sabbaga et al., 1993) 
10. ACTH-independent adrenal cortex hyperplasias 
ACTH-independent hypercortisolism is always of adrenocortical origin and an 
adrenocortical adenoma or carcinoma are by far its most common aetiologies (in up to 95% 
of patients). The remaining cases will be adrenocortical hyperplasias.  
Even in these cases it’s important to distinguish adrenocorticotropin (ACTH)–dependent 
forms like Cushing’s disease or CAH (due to 21-hydroxylase deficiency) from ACTH-
independent ones as a primary step in the differential diagnosis of Cushing’s syndrome due 
to adrenocortical bilateral hyperplasias (Doppman et al., 2000).  
Among the adrenal causes of Cushing’s syndrome about 10-15% are due to bilateral adrenal 
lesions that include micronodular (particularly its most common variant the Primary 
Pigmented Nodular Adrenocortical Disease – PPNAD) and macronodular adrenal hyperplasias 
(ACTH-Independent Macronodular Adrenocortical Hyperplasia - AIMAH) and, more rarely, 
bilateral adenomas or carcinomas (Christopoulos et al., 2005; Stratakis & Boikos, 2007).  
The hyperplasias can be sporadic or familial as is the case of PPNAD that can occur isolated 
or as part of an autosomal dominant disease including other tumors, endocrine and non-
endocrine, called the Carney Complex.  
Many adrenal cortex hyperplasia cases are thought to be the consequence of genetic changes 
in several key components of the cyclic AMP (cAMP) pathway (Libé & Betherat, 2005; 
Groussin et al., 2002a; Stratakis et al., 2007). Activating germline mutations of the ACTH 
receptor (MC2R) gene, making it display high levels of basal activity, have been reported 
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(Swords et al., 2002). The same occurred with GNAS activating mutations resulting in 
constitutive activation of the cAMP pathway that were shown to cause ACTH-independent 
macronodular adrenocortical hyperplasia (AIMAH) in McCune-Albright syndrome 
(Weinstein, 1991). On the other hand PRKAR1A-inactivating mutations resulting in a 
permanent activation of PKA may be associated to the development of PPNAD either 
isolated or as part of the Carney complex (Kirschner et al., 2000; Groussin et al., 2002b). 
More recently, inactivating mutations of the phosphodiesterase 11A gene, a gene coding for 
an enzyme that normally regulates cyclic nucleotide levels was reported both in cases of 
PPNAD and other bilateral hyperplasias (e.g. macronodular) (Libé et al., 2008).  
11. ACTH-independent macronodular hyperplasias 
The ACTH-independent macronodular adrenocortical hyperplasias (AIMAH) constitute a 
rare condition that consists of multiple bilateral adrenocortical macronodules causing a 
striking enlargement of the adrenal glands (Doppman et al., 1991; Malchoff et al., 1989; 
Swain et al., 1998). The great majority of AIMAH cases  is sporadic. AIMAH is responsible 
for less than 1% of all the endogenous cases of Cushing’s syndrome (Christopoulos et al., 
2005). Usually patients present in the fifth and sixth decades of life, a significantly latter age 
of onset compared to other cortisol producing adenomas (Swain et al., 1998).  
11.1 AIMAH pathogenesis 
Increased cortisol levels in AIMAH result from the fact that hormones other than ACTH 
become able to activate cortisol secretion through receptors aberrantly located in the adrenal 
cortex cells and coupled to cAMP activation. Hormones like GIP, catecholamines, 
vasopressin, serotonin, LH among others can activate PKA signaling, via cAMP production, 
leading to a situation of Cushing’s syndrome. 
In fact a great number of patients with AIMAH have that ectopic expression of and/or 
increased responsiveness to one of several possible receptors like the gastric inhibitory 
polypeptide (GIP) receptors (food-dependent hypercortisolism) (Resnik et al., 1992; N’diaye 
et al., 1998), vasopressin receptors (Horiba et al., 1995), the ǃ-adrenergic receptors (Lacroix et 
al., 1997), the LH receptors, the serotonin receptors, the leptin receptors and angiotensin II 
receptors (Lacroix et al., 1997; Lacroix et al., 2001; Lacroix et al., 1992). 
In the example of GIP-activated-cortisol-production, k cells from the duodenum and small 
intestine release, after food ingestion, a gastro-intestinal hormone named GIP (Gastric 
Inhibiting Peptide or Glucose-dependent Insulinotropic Peptide) in physiological 
concentrations (Lacroix et al., 2001). The expression of GIP receptors in the cells of the zona 
fasciculata, where they normally don’t exist, can then be activated by the GIP secreted in 
response to meals, causing what is known as “food-dependent” cortisol production. The 
presence of this receptor can be confirmed in vivo by clinical testing or by adrenal imaging 
following the injection of [123I]-GIP (Lacroix et al., 1992).  
To date, more than 30 cases were reported where the adrenal hormonal hypersecretion was 
associated to GIP stimulation. In the majority of cases patients presented with AIMAH 
(Lacroix et al., 2004; Groussin et al., 2002c). Besides that, other receptors were identified, 
some ectopically expressed and some being eutopic but showing  an over-expression in the 
adrenocortical cells, as being the cause of cases of AIMAH and recently also demonstrated 
in cases of unilateral adenomas (Lacroix, 2009). 
The majority of cases of AIMAH is sporadic. Some cases however are familial and in most 
an autosomal dominant hereditarity has been described (Lacroix, 2009). Nevertheless, the 
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genetic cause for these cases hasn’t yet been identified. In addition to those familiar reports, 
AIMAH has been described in MEN-1 with a frequency between 6% (Burgess et al., 1996) 
and 21% (Skogseid et al., 1992), and in rare cases of Gs alpha subunit mutations (Weinstein 
et al., 1991; Fragoso et al., 2003) or activating mutations of the ACTH receptor (MC2R) 
(Swords et al., 2002): 
 Gs alpha-subunit mutations — an activating mutation in the gene of the Gsa subunit 
of G-protein coupled receptors (stimulatory guanine nucleotide-binding protein, Gs) 
leads to constitutive activation of cAMP. These mutations may be responsible not 
only for increased production of cortisol but also for increased proliferation and 
consequently the formation of adrenal nodules (Weinstein et al., 1991; Fragoso et al., 
2003).   
 MEN1 – In patients with multiple endocrine neoplasia syndrome type 1 (MEN1) caused 
by mutations in the the tumor suppressor gene menin, together with the more frequent 
endocrine tumors that are characteristic of the syndrome, adrenocortical adenomas or 
macronodular bilateral hyperplasias may also occur (Burgess et al., 1996; Skogseid et al., 
1992). 
 Other genes – There were some rare reports of activating mutations of the ACTH receptor 
(MC2R) gene in adrenal tumors and AIMAH (Swords et al., 2002). Moreover, AIMAH has 
also been reported in patients with: familial polyposis coli and a mutation in the 
adenomatous polyposis coli (APC) gene (Kartheuser et al., 1999); in patients with 
mutations in the fumarate hydratase gene (FH) (Matyakhina et al., 2005) on chromosome 
1 (1q42.3-43); and in patients with germline mutations in phosphodiesterase 11A isoform 
4 gene (PDE11A) (Libé et al., 2008) located on chromosome 2 (2q31-35). 
11.2 AIMAH diagnosis and clinical presentation 
Usually AIMAH cases can be discovered after an incidental radiological finding or 
following the investigation of an adrenal hypersecretion syndrome and can be 
distinguished from ACTH-dependent macronodular hyperplasia by a suppressed plasma 
ACTH (<5 pg/mL vs. ≥15 pg/mL).  
The most common laboratory findings associated with AIMAH are the following: 
 Increased serum and urinary cortisol and undetectable plasma ACTH in the basal state 
(Doppman et al., 2000; Swain et al., 1998; Kirschner et al., 1964; Bourdeau et al., 2001, 
Lieberman et al., 1994). 
 As in any cause of adrenal cortisol hypersecretion, dexamethasone suppression test fails 
to suppress cortisol production (Christopoulos et al., 2005). 
An exception to this general pattern occurs in patients with GIP-dependent Cushing's 
syndrome in whom cortisol hypersecretion occurs in response to meals and serum cortisol 
may be low in the fasting state (Resnik et al., 1992; Lacroix et al., 1992). 
 Steroid hormone synthesis is relatively inefficient in AIMAH as a consequence of 
decreased steroidogenic enzymatic activity resulting frequently in elevated 17-
hydroxyprogesterone levels after stimulation with ACTH (Bourdeau et al., 2001). 
 Serum 18-hydroxycorticosterone, corticosterone and estrone may cause hypertension or 
feminization in the patients in whom they are increased (Wada et al., 2002).  
The diagnosis of AIMAH is usually suspected after typical imaging studies, which can be 
variable. At the computed tomography (CT) the adrenal glands in patients with AIMAH 
are greatly enlarged with multiple macronodules up to 5 cm in diameter. These adrenals’ 
weight may vary between 24 to 500g (Doppman et al., 2000; Malchoff et al., 1989).  
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The asymmetric appearance of the adrenal macronodules in AIMAH has been described 
(Liebermann et al., 1994; Lacroix et al., 2001) and also, according to a study  including 
patients with surgically proven AIMAH, adrenal masses measuring up to 5 cm of soft tissue 
density can distort and obscure the adrenal glands (Doppman et al., 1991). This may 
conduct to the erroneous diagnosis of a unilateral adenoma.  
Therefore, other clinical and molecular features must be used in diagnosing AIMAH.  
One important suggestion consist of evaluating all patients with AIMAH and clinical and 
sub-clinical Cushing’s syndrome for the presence of aberrant receptors, that are very 
frequently present in AIMAH (Lacroix et al., 2001; Mircescu et al., 2000). 
In this scenario, tests that modulate the levels of ligands for those receptors may be useful 
determining cortisol and other steroid changes. These tests include physiological tests, such 
as upright posture and mixed meals, and pharmacological tests including gonadotropin-
releasing hormone, thyrotropin-releasing hormone, vasopressin, glucagon and 
metoclopramide (Lacroix et al., 2001; Mircescu et al., 2000). Cortisol increases ≥25% are 
considered as significant, provided there is no increase in ACTH. If necessary, these tests 
should be carried out under Dexamethasone suppression. Responses between 25% and 49% 
are considered partial responses and if ≥50% complete responses. Any positive change 
should prompt the continuation of the study to identify all the receptors that may be 
involved (Lacroix et al., 2001) 
The importance of identifying these aberrant receptors is the possibility to have specific 
therapeutical weapons that may permit avoiding bilateral adrenalectomy: 
 
RECEPTOR IN VIVO SCREENING MEDICAL TREATMENT 
GIP 
Mixed meal (Food-dependent Cushing) 
Stimulation by GIP infusion 
Octreotide 
GIPR antagonist 
Vasopressin 
Upright posture 
Inhibition by water load 
Stimulation by saline infusion 
Administration of Arginine Vasopressin 
Administration of DDAVP (- =V1R; + =V2R) 
Vasopressin receptor 
antagonist 
DDAVP antagonist (V2) 
Β-adrenergic 
Upright posture 
Stimulation by insulin-induced hypoglycemia 
Isoproterenol infusion 
Propranolol suppression 
Β-blocker (Propranolol) 
LH / βHCG 
GnRH test 
hCG 
Recombinant LH 
Pregnancy or Menopausal related cortisol 
elevation  
Sometimes also androgen secreting 
Long acting GnRH agonist 
GnRH antagonist 
5HT-4  
Administration of 5HT-4 agonists 
Metoclopramide/Cisapride/Tegaserod test 
5HT-4 receptor antagonist 
Angiotensin  
Upright posture 
Angiotensin infusion (?) 
Angiotensin antagonist 
Angiotensin receptor 
antagonist 
(Adapted from Lacroix et al., 2009 ACTH independent macronodular hyperplasia. Best Practice and 
Research Clinical Endocrinology and Metabolism. Vol 23. Pp 245-259)  
Table 5. Receptors involved in AIMAH, in vivo screening tests and possible medical treatments 
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12. ACTH-independent micronodular hyperplasias 
ACTH-independent micronodular hyperplasias are characterized by the presence of 
multiple cortical micronodules, with less than 1 cm in diameter (Louiset et al., 2010). 
These micronodular hyperplasias can be divided in two different subtypes, depending on 
the presence or absence of nodular pigment and internodular atrophy. The most common 
and predominant type of ACTH-independent micronodular adrenal hyperplasia is the 
primary pigmented nodular adrenocortical disease (PPNAD), characterized by multiple 
pigmented micronodules usually surrounded by internodular cortical atrophy. The 
pigmented nodules are observed in the zone between the cortex and the medulla and the 
cells have hybrid characteristics between cortical and medullar (for instance the high 
expression of synaptophysin). The pigment has been identified as lipofuscin (Louiset et 
al., 2010).  
PPNAD is one of the possible causes of Cushing’s syndrome. However, it must be stressed 
that it is a rare disease representing less than 1% of the cases of Cushing’s syndrome. It may 
be sporadic or familial, and in this case it’s one of the components of the Carney complex 
(Carney & Young, 1992; Stratakis et al., 2001). 
12.1 ACTH-independent micronodular hyperplasia- pathogenesis 
A few genes were already identified as causal for the development of ACTH-independent 
micronodular hyperplasia: 
 PRKAR1A - Most patients with PPNAD, especially when the disease is a component 
of Carney complex, have germline-inactivating mutations of the PRKAR1A [protein 
kinase A (PKA) regulatory subunit type 1ǂ] gene (Kirschner et al., 2000; Groussin et 
al., 2002a; Groussin et al., 2002b). These mutations code for a truncated protein that is 
not produced, and the loss of this protein leads to an increased activation of protein 
kinase A (PKA) by cyclic AMP (Nadella & Kirschner, 2005). In several different 
studies of patients with PPNAD associated with Carney complex, 65-82% had 
PRKAR1A mutations (Groussin et al., 2002; Veugelers et al., 2004; Bertherat et al 
2009). 
 Phosphodiesterase 11A (PDE11A) - PDE11A is a dual-specificity PDE with affinity 
both to cAMP and cGMP, expressed in several endocrine tissues (D’Andrea et al., 
2005). Decreased expression of PDE11A has been correlated to increased 
adrenocortical levels of cAMP and cAMP-responsive element (CREB) 
phosphorylation presumably being the cause of adrenal hyperplasia. Besides having 
been identified in PPNAD and non-pigmented micronodular bilateral adrenocortical 
hyperplasias, in a study of Libé and colleagues, the PDE11A missense germline 
variants were also found in 18.8% of adrenocortical tumors (adrenocortical 
carcinomas, adenomas and bilateral macronodular adrenal hyperplasias) (Libé et al., 
2008). 
 Other genes - PDE8B gene mutations have also been described in patients with PPNAD 
or nonpigmented variants of the disease (Horvath et al., 2008).   
Moreover, in addition to germline PRKAR1A mutations, somatic beta-catenin mutations 
have been found in the larger nodules of patients with PPNAD, suggesting that secondary 
events in the Wnt/beta-catenin signaling pathway can contribute to tumorigenesis in 
PPNAD (Tadjine et al., 2008; Gaujoux et al., 2008). 
www.intechopen.com
 Adrenal Cortex Tumors and Hyperplasias 
 
337 
12.2 ACTH-independent micronodular hyperplasia – Diagnosis and clinical 
presentation 
Most commonly patients with PPNAD present signs and symptoms of hypercortisolism 
such as weight gain, obesity, hypertension, and menstrual cycle disorders. However, in 
many of them these symptoms are subtle and slowly progressive. Besides, sometimes the 
cortisol hypersecretion can be cyclical rendering these cases difficult to diagnose. On the 
other hand, there are several characteristics that are unique to this type of micronodular 
hyperplasia (Carney & Young, 1992; Larsen et al., 1986; Stratakis et al., 2001). 
 The majority of patients with PPNAD are diagnosed at a young age, usually before 
turning 30 years, and many cases occur in patients under 15 years of age.  
 Another hallmark is the paradoxical cortisol response to Dexamethasone suppression 
test, meaning that cortisol raises in response to dexamethasone instead of being reduced 
(Stratakis et al., 1999). 
 At surgery the characteristic pigmentation can be observed. 
 Most of the nodules found in these patients are less than 4 mm, and reasonably well 
demarcated from the adjacent atrophic cortex.  
As already mentioned, in some patients with this pathology the development of 
hypercortisolism symptoms can be cyclic and irregular what causes some typical Cushing’s 
syndrome symptoms to be variable or discrete, therefore complicating its diagnosis. On the 
other hand, in patients with PPNAD, due to the presence of elevated cortisol levels, 
osteoporosis and avascular hip necrosis have been reported (Ruder et al., 1974; Carney & 
Young, 1992).  
12.3 Carney complex 
PPNAD occurs as part of Carney complex in more than 60% of the cases (Bertherat et al., 
2009). 
This syndrome is an autosomal dominant form of multiple neoplasia. The main signs that 
characterize this condition are the presence of spotty skin pigmentation (lentiginosis), the 
presence of endocrine tumors, including PPNAD (the most common endocrine finding in 
Carney's complex), testicular large cell calcifying Sertoli cells tumors, GH secreting pituitary 
adenomas and thyroid adenomas and carcinomas, and non-endocrine tumors, including 
atrial myxomas, cutaneous myxomas, breast ductal adenomas, psammomatous melanotic 
schwannomas, and osteochondromyxomas (Stratakis et al., 2001; Carney et al., 1985; 
Stratakis et al., 1997).  Cushing’s syndrome caused by PPNAD occurs in many of the cases of 
Carney Complex. However, if one considers also the subclinical cases of Cushing’s 
syndrome, the percentage will surely be higher (Bertherat et al., 2009; Stratakis et al., 2001).  
Three genetic loci were associated with the Carney Complex: 2p16, 17q22-24 and 17p12-
13. More than 70% Carney Complex cases have a PRKAR1A mutation (Bertherat et al., 
2009). 
For being a heterogeneous disease that can present with different signs and symptoms, its 
diagnosis is usually difficult (Carson et al., 1988; Gunther et al., 2004), especially if it shows 
unusual clinical manifestations and if it is not present in other family members.  
The most important steps for its diagnosis can be the same as for the diagnosis of Cushing’s 
syndrome. Therefore initial phases must include confirming hypercortisolism, determining 
whether the hypercortisolism is ACTH-dependent or ACTH-independent, and whether 
there is paradoxical response to Dexamethasone suppression test. Then it will be necessary 
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to identify the cause of that hypercortisolism. When investigating family members of 
patients affected by PPNAD or other forms of micronodular disease, the dexamethasone 
suppression tests should be used to identify subclinical adrenal disease, since for these 
patients, even subtle changes of cortisol secretion should be considered abnormal (plasma 
cortisol >1.8 µg/dL [50 nmol/L] following Liddle's test). ACTH suppression is also 
significant in this context.  After that, the computerized tomography of the adrenals will 
help to distinguish unilateral from bilateral nodular disease or hyperplasia and so it must be 
performed next (Rockal et al., 2004).  It must be stressed however that the adrenals are not 
very enlarged and so the interpretation of the images can be difficult (Bertherat et al., 2009). 
Treatment of PPNAD is often bilateral adrenalectomy, sometimes in two surgical timings 
years-apart, related to the fact that the development of this bilateral disease is frequently 
asymmetrical.  
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